Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Xudong Wei

Chris Hugh Senanayake

Nizar Haddad

Nathan K Yee

Rogelio Perez Frutos

Carl Alan Busacca

Suresh R Kapadia

Bo Qu

Nitinchandra D Patel

Anjan Saha

Peter Nickolaus

Soojin Kim

Ulrike Werthmann

Fabrice Gallou

Jon Charles Lorenz

Bing-Shiou Yang

Thomas Gabriel Tampone

Jason Alan Mulder

Wenjun Tang

Jinghua Xu

Pascale A J Pouzet

Jolaine Savoie

Jianxiu Liu

Yibo Xu

Azad Hossain

Li Feng Zhang

Xiao-Jun Wang

Thomas Nicola

Lana Louise Smith Keenan

Robert Simpson

Juergen Schnaubelt

Sonia Rodriguez

Joerg Brandenburg

Dirk Kemmer

Jutta Kroeber

Dieter Gutheil

Vittorio Farina

Robert Hagenkoetter

Pascale Arielle Jane-Josee Pouzet

Kai Oliver Donsbach

Michael Schul

Hans-Dieter Ecker

Eric Winter

Isabelle Gallou

Chris Hugh Sananayake

Piperidino-dihydrothienopyrimidine sulfoxides of formula I wherein:

Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma

The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms andwherein R is Cl andwherein R may be located either in the para-, meta- or ortho-position of Ring A,wherein S* is a sulphur atom that represents a chiral center,and all pharmaceutically acceptable salts, enantiomers and racemates, hydrates and solvates thereof and the use of these compounds for the treatment of inflammatory or allergic diseases of the respiratory tract such as COPD or asthma.

Phosphine ligands of the formula Ia, IB and mixtures thereof. 

Monophosphorus ligands and their use in cross-coupling reactions

Disclosed is a compound of formula (I) and salts thereof. Also disclosed are methods of making the compound of formula (I) and the use of the compound as an intermediate for making pharmaceutically active compounds such as 11-&#x3b2;-hydroxysteroid hydrogenase type 1 (11-&#x3b2;-HSD1) inhibitors.

Indenopyridine derivatives

The invention relates to a series of novel chiral nitrogen-phosphorus ligands of formulae (Ia) and (Ib): wherein R-Rand X are as defined herein. The invention also relates to chiral metal complexes prepared with these chiral nitrogen-phosphorus ligands. The chiral metal complexes are useful as catalysts for carrying out asymmetric hydrogenation.

Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes

Disclosed are methods for the preparation of bromo-substituted quinolines of the formula (I) where R is aryl, heteroaryl, alkyl, alkenyl or alkynyl, which are useful as intermediates in the preparation of agents for the treatment of hepatitis C viral (HCV) infections: Formula (I). 

Process for preparing bromo-substituted quinolines

The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, 

The invention relates to a series of novel chiral phosphorus ligands of formulae (Ia) and (Ib): wherein R, 1-rR&#x3e;4 and X are as defined herein. The invention also relates to chiral metal complexes prepared with these chiral phosphorus ligands. The chiral metal complexes are useful as catalysts for carrying out asymmetric hydro genation. 

Chiral phosphorus ligands

Disclosed is a process for preparing a macrocyclic compound of the formula (I) wherein a hydroxyl-substituted macrocyclic compound of formula (3) is reacted with a sulfonyl-substituted compound of formula QUIN:  The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.

Process for preparing macrocyclic compounds

Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection:  The disclosed processes use SAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.

Process for preparing acyclic HCV protease inhibitors

Intermediates of the formula QUIN: and methods for their preparation are described. The intermediate compounds are useful for preparing active agents for the treatment of hepatitis C virus (HCV) infection.

The invention relates to the field of pharmaceutics and more specifically to cycloalkylamidoacid compositions useful in the preparation of cycloalkyaminoacids and oxazolidinediones, and processes for making cycloamidoacids X and R are defined herein.

Cycloalkylamidoacid compounds, processes for making and uses thereof

Growing community of inventors

Ridgefield, CT, United States of America

Xudong Wei